James Sullivan
Directeur Technique/Scientifique/R&D chez ENGENE HOLDINGS INC.
Postes actifs de James Sullivan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ENGENE HOLDINGS INC. | Directeur Technique/Scientifique/R&D | 01/11/2023 | - |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Directeur Technique/Scientifique/R&D | 01/02/2022 | - |
Historique de carrière de James Sullivan
Anciens postes connus de James Sullivan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TRANSLATE BIO, INC. | Corporate Officer/Principal | 01/01/2021 | 01/02/2022 |
| SANA BIOTECHNOLOGY, INC. | Directeur/Membre du Conseil | 01/08/2019 | 01/01/2021 |
| Corporate Officer/Principal | 01/08/2019 | 01/01/2021 |
Formation de James Sullivan
| Boston College | Undergraduate Degree |
| University College Dublin | Graduate Degree |
| Boston University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Canada | 3 |
| Irlande | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| ENGENE HOLDINGS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Bourse
- Insiders
- James Sullivan
- Expérience
